How much does Rucaparib cost? latest quote

Rucaparib (Rucaparib) is a representative PARP inhibitor anti-cancer targeted drug. It was initially approved by the US FDA in December 2016 for the treatment of ovarian cancer and other related solid tumors. Its research and development background is based on in-depth research on the DNA damage repair mechanism. By inhibiting the activity of polyadenosine diphosphate ribose polymerase (PARP) enzyme, tumor cells are blocked in the process of repairing damaged DNA, ultimately leading to cancer cell apoptosis. Compared with traditional chemotherapy, this type of drug is more precise and can target patients carrying BRCA gene mutations, so it has high clinical application value.

Currently, rucapanib has not been officially launched in the country, so it has not yet been included in the scope of medical insurance payment. In overseas markets, the common specifications of rucapanib are300mg*60 tablets, and the price is about 38,000 yuan. Although the prices vary slightly depending on the country and sales channel, the overall price is high for innovative drugs. It is worth noting that there is currently no generic version of rucapanib, so if patients need to use it, they mainly rely on imported channels, which imposes a heavy cost burden.

From the perspective of the international market, the pricing of rucapanib not only reflects its R&D and clinical value, but is also affected by the patent protection of pharmaceutical companies. Domestic patients in need of treatment often obtain drugs through cross-border drug purchase or overseas medical service institutions, which to a certain extent increases the inconvenience of medication. In the future, with the gradual promotion of drugs around the world and the expiration of patents, if generic drugs can enter the market, the price may drop, thus benefiting more patient groups.

In the context of the rapid development of targeted tumor therapy, rucapanib is one of the representativePARP inhibitors. Its indications and market price have always been core issues of concern to patients and doctors. With the promotion of the introduction of imported innovative drugs at the policy level, rucapanib is expected to enter the domestic market and gradually be included in medical insurance in the future, providing patients with more accessible treatment options.

Reference materials:https://www.drugs.com/mtm/rucaparib.html